Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti CD19 and anti BCMA CAR T cell therapy - Yake Biotechnology

Next Previous
Drug Profile

Anti CD19 and anti BCMA CAR T cell therapy - Yake Biotechnology

Alternative Names: Anti-CD19/BCMA CART cell therapy - Yake Biotechnology; CD19/BCMA CAR T-cells; CD19/BCMA CAR T-cells injection; CD19/BCMA Targeted CAR T-cells - Yake Biotechnology

Latest Information Update: 28 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yake Biotechnology
  • Developer Yake Biotechnology; Zhejiang University
  • Class Anti-inflammatories; Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Amyloidosis; Autoimmune haemolytic anaemia; Multiple myeloma; Nephritis; Non-Hodgkin's lymphoma; POEMS syndrome; Precursor B-cell lymphoblastic leukaemia-lymphoma; Scleroderma; Sjogren's syndrome; Systemic lupus erythematosus; Vasculitis

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for phase-I development in Amyloidosis(Treatment-experienced) in China (IV, Infusion)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Autoimmune-haemolytic-anaemia(Treatment-experienced) in China (IV, Infusion)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Nephritis(In children, In the elderly, Treatment-experienced, In adults) in China (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top